The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience.

Abstract:

BACKGROUND:There are limited economic evaluations comparing coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) for multi-vessel coronary artery disease (MVCAD) in contemporary, routine clinical practice. OBJECTIVE:The aim was to perform a cost-effectiveness analysis comparing CABG and PCI in patients with MVCAD, from the perspective of the Australian public hospital payer, using observational data sources. METHODS:Clinical data from the Melbourne Interventional Group (MIG) and the Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) registries were analysed for 1022 CABG (treatment) and 978 PCI (comparator) procedures performed between June 2009 and December 2013. Clinical records were linked to same-hospital admissions and national death index (NDI) data. The incremental cost-effectiveness ratios (ICERs) per major adverse cardiac and cerebrovascular event (MACCE) avoided were evaluated. The propensity score bin bootstrap (PSBB) approach was used to validate base-case results. RESULTS:At mean follow-up of 2.7 years, CABG compared with PCI was associated with increased costs and greater all-cause mortality, but a significantly lower rate of MACCE. An ICER of $55,255 (Australian dollars)/MACCE avoided was observed for the overall cohort. The ICER varied across comparisons against bare metal stents (ICER $25,815/MACCE avoided), all drug-eluting stents (DES) ($56,861), second-generation DES ($42,925), and third-generation of DES ($88,535). Moderate-to-low ICERs were apparent for high-risk subgroups, including those with chronic kidney disease ($62,299), diabetes ($42,819), history of myocardial infarction ($30,431), left main coronary artery disease ($38,864), and heart failure ($36,966). CONCLUSIONS:At early follow-up, high-risk subgroups had lower ICERs than the overall cohort when CABG was compared with PCI. A personalised, multidisciplinary approach to treatment of patients may enhance cost containment, as well as improving clinical outcomes following revascularisation strategies.

authors

Ariyaratne TV,Ademi Z,Huq M,Rosenfeldt F,Duffy SJ,Parkinson B,Yap CH,Smith J,Billah B,Yan BP,Brennan AL,Tran L,Reid CM

doi

10.1007/s40258-018-0407-5

subject

Has Abstract

pub_date

2018-10-01 00:00:00

pages

661-674

issue

5

eissn

1175-5652

issn

1179-1896

pii

10.1007/s40258-018-0407-5

journal_volume

16

pub_type

杂志文章
  • Health Insurance in Sub-Saharan Africa: A Scoping Review of the Methods Used to Evaluate its Impact.

    abstract::We conducted a scoping review with the objective of synthesizing available literature and mapping what designs and methods have been used to evaluate health insurance reforms in sub-Saharan Africa. We systematically searched for scientific and grey literature in English and French published between 1980 and 2017 using...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-019-00499-y

    authors: Degroote S,Ridde V,De Allegri M

    更新日期:2020-12-01 00:00:00

  • Economic analysis of thrombo inCode, a clinical-genetic function for assessing the risk of venous thromboembolism.

    abstract:BACKGROUND:Patients with venous thromboembolism (VTE) commonly have an underlying genetic predisposition. However, genetic tests nowadays in use have very low sensitivity for identifying subjects at risk of VTE. Thrombo inCode(®) is a new genetic tool that has demonstrated very good sensitivity, thanks to very good cov...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-015-0153-x

    authors: Rubio-Terrés C,Soria JM,Morange PE,Souto JC,Suchon P,Mateo J,Saut N,Rubio-Rodríguez D,Sala J,Gracia A,Pich S,Salas E

    更新日期:2015-04-01 00:00:00

  • Costs to hospitals of acquiring and processing blood in the US: a survey of hospital-based blood banks and transfusion services.

    abstract:BACKGROUND:little is known about the economics of acquiring and processing the more than 14 million units of red blood cells used annually in the US. OBJECTIVE:to determine the average price paid by hospitals to suppliers for a unit of red blood cells and to identify cost variations by region and facility type and siz...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11530740-000000000-00000

    authors: Toner RW,Pizzi L,Leas B,Ballas SK,Quigley A,Goldfarb NI

    更新日期:2011-01-01 00:00:00

  • Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review.

    abstract:BACKGROUND:Cervical cancer ranks fourth amongst the commonest malignancies worldwide and the second most prevalent cancer afflicting women in low-to-middle income countries (LMICs), hence, of great public health importance. LMICs are the most affected regions as evidenced by their high prevalence of the disease. Mortal...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-020-00576-7

    authors: Okeah BO,Ridyard CH

    更新日期:2020-10-01 00:00:00

  • Why does economic analysis in health care not get implemented more? Towards a greater understanding of the rules of the game and the costs of decision making.

    abstract::Despite recent initiatives across a number of countries to institutionalise the use of economic evaluation in the assessment of new technologies, the evidence suggests that, to date, the impact of economic analysis on health sector decision making in practice has been low. This paper proposes that incentive compatibil...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:

    authors: Jan S

    更新日期:2003-01-01 00:00:00

  • Current and future economic burden of osteoporosis in New Zealand.

    abstract:BACKGROUND:Osteoporosis is recognized as a serious health condition in developed as well as developing countries. There are no accurate estimates of the extent of the burden of osteoporosis in New Zealand. The purpose of this study was to estimate the economic burden of osteoporosis in New Zealand using data from inter...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11531500-000000000-00000

    authors: Brown P,McNeill R,Leung W,Radwan E,Willingale J

    更新日期:2011-03-01 00:00:00

  • Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.

    abstract::The rapid rise in pharmaceutical costs in France has been driven by new technologies and the growing prevalence of chronic diseases as well as considerable prescribing freedom and choice of physician among patients. This has led to the introduction of a number of reforms and initiatives in an attempt to moderate expen...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03256162

    authors: Sermet C,Andrieu V,Godman B,Van Ganse E,Haycox A,Reynier JP

    更新日期:2010-01-01 00:00:00

  • Does Insurance Status Influence a Patient's Hospital Charge?

    abstract:BACKGROUND:There is obscurity regarding how US hospitals determine patients' charges. Whether insurance status influences a patient's hospital charge has not been explored. OBJECTIVE:The objective of this study was to determine whether hospitals charge patients differently based on their insurance status. METHODS:Thi...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-017-0308-z

    authors: Woodworth L,Romano PS,Holmes JF

    更新日期:2017-06-01 00:00:00

  • Reducing smoking prevalence in Australian prisons: a review of policy options.

    abstract::Smoking of tobacco products is a major public health challenge in prison settings in most countries. Although tobacco use was tolerated by custodial authorities for many decades, the overwhelming evidence of the adverse public health effects of tobacco on both the smokers and those in the vicinity of exhaled or passiv...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:

    authors: Awofeso N

    更新日期:2002-01-01 00:00:00

  • Inflammatory Bowel Diseases (Crohn´s Disease and Ulcerative Colitis): Cost of Treatment in Serbia and the Implications.

    abstract:BACKGROUND:Although the costs of treating inflammatory bowel disease (IBD) in developed countries are well established, they remain largely unknown in countries with recent histories of socio-economic transition including Serbia. OBJECTIVE:To estimate the costs of treatment including the resources used by patients wit...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0272-z

    authors: Kostić M,Djakovic L,Šujić R,Godman B,Janković SM

    更新日期:2017-02-01 00:00:00

  • Health State Utility Values for Age-Related Macular Degeneration: Review and Advice.

    abstract::Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de novo utility values in AMD. We describe how utility values have been used in heal...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-016-0275-9

    authors: Butt T,Tufail A,Rubin G

    更新日期:2017-02-01 00:00:00

  • Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.

    abstract:BACKGROUND:Treatment with antipsychotic medication is an important element of relapse prevention in the management of schizophrenia, and can reduce inpatient stays. Recently, the long-acting atypical antipsychotic paliperidone long-acting injectable (PLAI), a once-monthly LAI antipsychotic, was approved for treatment o...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0050-0

    authors: Zeidler J,Mahlich J,Greiner W,Heres S

    更新日期:2013-10-01 00:00:00

  • A Systematic Review of Studies Evaluating the Cost Utility of Screening High-Risk Populations for Latent Tuberculosis Infection.

    abstract:BACKGROUND:As tuberculosis screening trends to targeting high-risk populations, knowing the cost effectiveness of such screening is vital to decision makers. OBJECTIVES:The purpose of this review was to compile cost-utility analyses evaluating latent tuberculosis infection (LTBI) screening in high-risk populations tha...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-015-0183-4

    authors: Campbell JR,Sasitharan T,Marra F

    更新日期:2015-08-01 00:00:00

  • Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use.

    abstract:OBJECTIVES:To describe how post-market utilisation analysis in Australia informs cost-effectiveness assessment and pricing decisions, using aflibercept and ranibizumab as case studies. METHODS:Pharmaceutical claims were used to identify initiators of aflibercept and ranibizumab in the year after aflibercept-listing (D...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-018-0440-4

    authors: Kemp-Casey A,Pratt N,Ramsay E,Roughead EE

    更新日期:2019-06-01 00:00:00

  • Propensity-score matching in economic analyses: comparison with regression models, instrumental variables, residual inclusion, differences-in-differences, and decomposition methods.

    abstract::This paper examines the use of propensity score matching in economic analyses of observational data. Several excellent papers have previously reviewed practical aspects of propensity score estimation and other aspects of the propensity score literature. The purpose of this paper is to compare the conceptual foundation...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-013-0075-4

    authors: Crown WH

    更新日期:2014-02-01 00:00:00

  • Inclusion of compliance and persistence in economic models: past, present and future.

    abstract::Economic models are developed to provide decision makers with information related to the real-world effectiveness of therapeutics, screening and diagnostic regimens. Although compliance with these regimens often has a significant impact on real-world clinical outcomes and costs, compliance and persistence have histori...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/BF03261872

    authors: Kadambi A,Leipold RJ,Kansal AR,Sorensen S,Getsios D

    更新日期:2012-11-01 00:00:00

  • Financial risk of the biotech industry versus the pharmaceutical industry.

    abstract::The biotech industry now accounts for a substantial and growing proportion of total R&D spending on new medicines. However, compared with the pharmaceutical industry, the biotech industry is financially fragile. This article illustrates the financial fragility of the biotech and pharmaceutical industries in the US and...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/BF03256149

    authors: Golec J,Vernon JA

    更新日期:2009-01-01 00:00:00

  • A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.

    abstract::This article aims to define a value-based approach to pricing and reimbursement for off-patent originators using a multiple criteria decision analysis (MCDA) approach centered on a systematic analysis of current pricing and reimbursement policies in China. A drug price policy review was combined with a quantitative an...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-014-0150-5

    authors: Hu S,Zhang Y,He J,Du L,Xu M,Xie C,Peng Y,Wang L

    更新日期:2015-08-01 00:00:00

  • The Cost Effectiveness of Maintenance Schedules Following Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease: An Economic Evaluation Alongside a Randomised Controlled Trial.

    abstract:BACKGROUND:Chronic obstructive pulmonary disease (COPD) affects approximately 3 million people in the UK. An 8-week pulmonary rehabilitation (PR) course is recommended under current guidelines. However, studies show that initial benefits diminish over time. OBJECTIVE:We present here an economic evaluation conducted al...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40258-015-0199-9

    authors: Burns DK,Wilson EC,Browne P,Olive S,Clark A,Galey P,Dix E,Woodhouse H,Robinson S,Wilson A

    更新日期:2016-02-01 00:00:00

  • Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval.

    abstract:OBJECTIVE:Compared to traditional drugs, specialty drugs tend to be indicated for lower prevalence diseases. Our objective was to compare the potential population health benefits associated with specialty and traditional drugs in the year following product approval. METHODS:First, we created a dataset of estimates of ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0291-9

    authors: Chambers JD,Thorat T,Wilkinson CL,Salem M,Subedi P,Kamal-Bahl SJ,Neumann PJ

    更新日期:2017-04-01 00:00:00

  • The impact of rural health care accessibility on cancer-related behaviors and outcomes.

    abstract:BACKGROUND:This research seeks to identify the relationship between economic factors related to the ability to receive and pay for health services and adverse cancer outcomes, as well as preventative screening and behavioral factors that influence the risk of cancer. We focus on the Northern High Plains region, where w...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-014-0099-4

    authors: Belasco EJ,Gong G,Pence B,Wilkes E

    更新日期:2014-08-01 00:00:00

  • SecurAcath for Securing Peripherally Inserted Central Catheters: A NICE Medical Technology Guidance.

    abstract::Central venous catheters are commonly used to deliver therapies and to monitor patients, and require securing at the point of percutaneous entry to avoid dislodgement. SecurAcath is a catheter securement device designed for central venous catheters. The National Institute for Health and Care Excellence, as a part of i...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-018-0427-1

    authors: Macmillan T,Pennington M,Summers JA,Goddard K,Zala D,Herz N,Peacock JL,Keevil S,Chalkidou A

    更新日期:2018-12-01 00:00:00

  • Measuring Efficiency of Health Systems of the Middle East and North Africa (MENA) Region Using Stochastic Frontier Analysis.

    abstract:OBJECTIVE:The main purpose of this study is to measure the technical efficiency of twenty health systems in the Middle East and North Africa (MENA) region to inform evidence-based health policy decisions. In addition, the effects of alternative stochastic frontier model specification on the empirical results are examin...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-016-0230-9

    authors: Hamidi S,Akinci F

    更新日期:2016-06-01 00:00:00

  • Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.

    abstract:BACKGROUND:Antiplatelet therapy plays a central role in the prevention of atherothrombotic events. Both acetylsalicylic acid (aspirin) and clopidogrel have been shown to reduce the risk of recurrent cardiovascular events in various subgroups of patients with vascular disease. OBJECTIVE:To estimate the cost effectivene...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11535520-000000000-00000

    authors: Logman JF,Heeg BM,Herlitz J,van Hout BA

    更新日期:2010-01-01 00:00:00

  • Listening to the decision makers: sustainability of PBMA in Alberta.

    abstract:BACKGROUND:Decision makers within the Calgary Health Region adopted and applied programme budgeting and marginal analysis (PBMA) for priority-setting activity across major service portfolios within the Region. METHODS:Seventeen in-depth qualitative interviews were conducted with senior managers and clinicians to gain ...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/00148365-200403030-00005

    authors: Mitton C,Patten S,Donaldson C

    更新日期:2004-01-01 00:00:00

  • Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model.

    abstract:BACKGROUND:European guidelines advocate the measurement of on-treatment hepatitis C virus (HCV) RNA in order to determine optimal therapy duration (response-guided therapy [RGT]) in patients with rapid virological response (RVR) or delayed virological response (DVR). Treatment response is highly dependent upon the exte...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.1007/s40258-012-0002-0

    authors: McEwan P,Kim R,Yuan Y

    更新日期:2013-02-01 00:00:00

  • Virtual Touch™ Quantification to Diagnose and Monitor Liver Fibrosis in Hepatitis B and Hepatitis C: A NICE Medical Technology Guidance.

    abstract::Virtual Touch™ Quantification (VTq) is a software application used with Siemens Acuson ultrasound scanners to assess the stiffness of liver tissue. The National Institute for Health and Care Excellence (NICE) Medical Technologies Advisory Committee (MTAC) selected VTq for evaluation and invited the company to submit c...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-016-0277-7

    authors: Summers JA,Radhakrishnan M,Morris E,Chalkidou A,Rua T,Patel A,McMillan V,Douiri A,Wang Y,Ayis S,Higgins J,Keevil S,Lewis C,Peacock J

    更新日期:2017-04-01 00:00:00

  • Organization and estimated patient-borne costs of oral anticoagulation therapy in Italy: results from a survey.

    abstract:BACKGROUND:The management of the large patient population in Italy receiving long-term oral anticoagulation therapy (OAT) poses organizational challenges that are traditionally approached with a centralized procedure, relying on hospital-based clinics and/or GPs. However, the availability of near-patient testing device...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章

    doi:10.2165/11313890-000000000-00000

    authors: Pradelli L,Iannazzo S,Zaniolo O,Botrugno P

    更新日期:2010-01-01 00:00:00

  • Curos™ Disinfection Caps for the Prevention of Infection When Using Needleless Connectors: A NICE Medical Technologies Guidance.

    abstract::Central line-associated bloodstream infections (CLABSIs) are primary, laboratory confirmed bloodstream infections in patients with a central line within 48 h of symptom onset. Catheter-related bloodstream infection (CRBSI) is a more specific term used when the cause of infection has been confirmed by catheter tip cult...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-020-00602-8

    authors: O'Connell S,Dale M,Morgan H,Carter K,Carolan-Rees G

    更新日期:2020-08-05 00:00:00

  • The Memokath-051 Stent for the Treatment of Ureteric Obstruction: A NICE Medical Technology Guidance.

    abstract::Memokath-051 is a thermo-expandable, nickel-titanium alloy spiral stent used to treat ureteric obstruction resulting from malignant or benign strictures. The National Institute for Health and Care Excellence (NICE) selected Memokath-051 for evaluation. The company, PNN Medical, claimed Memokath-051 has clinical superi...

    journal_title:Applied health economics and health policy

    pub_type: 杂志文章,评审

    doi:10.1007/s40258-018-0389-3

    authors: Eaton Turner E,Jenks M,McCool R,Marshall C,Millar L,Wood H,Peel A,Craig J,Sims AJ

    更新日期:2018-08-01 00:00:00